BA-3011 is a novel conditionally active biologic AXL-targeted antibody-drug conjugate used to treat solid tumor. The CAB technology is aimed to improve the selectivity of BA-3011 for binding to AXL receptor on cancer cells.
Catalog Number | Size | Price | Quantity |
---|---|---|---|
BADC-00030 | -- | $-- |